Examkin

Soru

Zorluk: OrtaPharmacologic Interventions

During a routine follow-up appointment, a physician evaluates a female patient who reports 33 weeks of progressive exertional dyspnea, orthopnea, and lower extremity swelling. The patient is 6868 years old and has a past medical history significant for type 22 diabetes mellitus, essential hypertension, and osteoarthritis. Her home medication regimen consists of metformin, pioglitazone, lisinopril, amlodipine, and daily naproxen.

On physical examination, her blood pressure is 145/88 mmHg145/88\text{ mmHg}, heart rate is 86/min86/\text{min}, and respiratory rate is 18/min18/\text{min}. Jugular venous distention is present at 8 cm8\text{ cm} above the sternal angle. Auscultation of the lungs reveals fine bibasilar crackles. The lower extremities exhibit 2+2+ bilateral pitting edema. A comprehensive metabolic panel is unremarkable, with a serum creatinine of 1.1 mg/dL1.1\text{ mg/dL}. A recent transthoracic echocardiogram demonstrates a left ventricular ejection fraction of 32%32\% with global hypokinesis.

Based on the current clinical findings and medication profile, which of the following pharmacologic interventions are appropriate for this patient? (Select all that apply)

  1. Discontinue pioglitazoneCevap
  2. Discontinue naproxenCevap
  3. Initiate oral furosemideCevap
  4. D
    Discontinue metformin
  5. E
    Initiate oral diltiazem

Cevap

The correct interventions are to discontinue pioglitazone, discontinue naproxen, and initiate oral furosemide.
This patient presents with new-onset symptomatic heart failure with reduced ejection fraction (HFrEF) accompanied by significant volume overload. Optimal management requires simultaneous medication reconciliation and initiation of symptom-relieving therapy. Pioglitazone (a thiazolidinedione) causes fluid retention by acting on the renal collecting ducts and is contraindicated in symptomatic heart failure. Naproxen (an NSAID) inhibits prostaglandins, reducing renal blood flow and promoting sodium retention, which blunts diuretic efficacy and worsens congestion. Both must be discontinued. Concurrently, a loop diuretic such as oral furosemide must be initiated to effectively manage her hypervolemia and relieve her dyspnea and edema.

Adım Adım Çözüm

1
Identify the primary clinical problem and its severity.
The patient has newly diagnosed heart failure with reduced ejection fraction (HFrEF) presenting with overt volume overload.
Symptoms of exertional dyspnea and orthopnea, signs of elevated JVD, crackles, and edema, combined with an ejection fraction of 32% confirm decompensated HFrEF.
2
Evaluate the current medication list for agents that exacerbate heart failure.
Pioglitazone and naproxen are identified as harmful in this setting.
Both medications independently promote sodium and water retention, which directly worsens pulmonary and systemic congestion.
3
Determine the necessary pharmacologic additions for acute symptom management.
A loop diuretic, such as oral furosemide, must be added.
The patient has significant clinical signs of fluid overload that require prompt diuresis to relieve symptoms and restore euvolemia.
4
Review remaining interventions for appropriateness regarding HFrEF contraindications.
Metformin should be continued, and non-dihydropyridine calcium channel blockers (like diltiazem) should be avoided.
Metformin is safe in HF without severe renal impairment. Non-DHP CCBs are contraindicated due to negative inotropic effects that can further compromise cardiac output.

Anahtar Kavram

Medication reconciliation in newly diagnosed HFrEF requires discontinuing fluid-retaining agents (NSAIDs, TZDs) and avoiding negative inotropes (non-DHP CCBs), while promptly initiating loop diuretics for volume overload.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru